Immunotherapy
Page 1 • 10 itemsUnlock global immunotherapy market insights. NovaPharmaNews delivers critical intelligence for pharma BD, investors & analysts. Stay ahead.
Tempest Therapeutics TPST-2003 CAR-T Shows Promise for Multiple Myeloma at ISCT 2026
Tempest Therapeutics presents positive TPST-2003 dual-targeting CAR-T data for relapsed/refractory multiple myeloma patients at ISCT 2026 meeting.
Greenwich LifeSciences GLSI-100 Abstract Accepted at ASCO 2026 for Breast Cancer Immunotherapy Trial
Greenwich LifeSciences announces ASCO 2026 abstract acceptance for GLSI-100, a Fast Track designated immunotherapy in Phase III trials for breast cancer recurrence prevention.
Tempest Therapeutics Achieves Manufacturing Milestone for TPST-2003 CAR-T Cancer Treatment
Tempest Therapeutics hits key manufacturing milestone for TPST-2003 dual-targeting CAR-T therapy, supporting Q4 2026 registrational study launch.
Mabwell 9MW2821 Combination Therapy Data to Be Presented at ASCO 2026 for Urothelial Carcinoma Treatment
Mabwell presents clinical data on 9MW2821 plus toripalimab combination therapy for urothelial carcinoma at ASCO 2026 Annual Meeting in Chicago.
Innovent Biologics IBI363 Clinical Data to Be Presented at ASCO 2026 Annual Meeting
Innovent Biologics announces new clinical data for IBI363, a PD-1/IL-2α bispecific fusion protein immunotherapy, will be presented at ASCO 2026.
Obsidian Therapeutics OBX-115 Phase 2 Melanoma Data to Be Presented at ASCO 2026
Obsidian Therapeutics will present Phase 2 clinical trial results for OBX-115, an autologous TIL cell therapy for advanced melanoma at ASCO 2026.
Abogen's ABO2203 mRNA Cancer Therapy Shows Promise in First-in-Human B-Cell Lymphoma Trial at AACR 2026
Abogen presents preliminary results of ABO2203, an innovative mRNA-encoded bispecific T-cell engager for relapsed/refractory B-cell lymphoma treatment.
Verismo Therapeutics SynKIR-110 Shows Promising Safety Profile in Phase 1 STAR-101 Trial for Advanced Solid Tumors
Verismo's SynKIR-110 KIR-CAR therapy demonstrates favorable safety and dose-dependent efficacy in Phase 1 trial for advanced solid tumors with no dose-limiting toxicities.
Akeso's Cadonilimab Shows Promising Survival Benefit in Advanced Pancreatic Cancer Phase II Trial
Akeso's first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab demonstrates survival benefit in advanced pancreatic cancer COMPASSION-26 trial.
Innate Pharma IPH5201 MATISSE Phase 2 Results Selected for AACR 2026 Clinical Trials Plenary Session
Innate Pharma's IPH5201 anti-CD39 antibody shows encouraging interim results in NSCLC, earning prestigious AACR 2026 plenary session presentation slot.